- 2,172
- 16
- Joined
- Jul 9, 2007
I've been following this company for a couple months. If you want to really take a gamble that could see you come up anywhere from 2x to 10x, invest in shares of Alimera Sciences (ticker:ALIM)
They are currently designing a drug that would help those suffering with disease in the retina. The drug was recently denied by the FDA, and we've seen 52 week highs of $11.40 drop to today's price of ~$1.30. However, Europe is expected to approve the drug in the next couple weeks, and if so, I predict the stock will go to at least $4.
And an article published today, http://stks.co/1SCJ
Here is some background on the FDA rejecting the drug, which leads me to believe Europe will accept it:
They are currently designing a drug that would help those suffering with disease in the retina. The drug was recently denied by the FDA, and we've seen 52 week highs of $11.40 drop to today's price of ~$1.30. However, Europe is expected to approve the drug in the next couple weeks, and if so, I predict the stock will go to at least $4.
And an article published today, http://stks.co/1SCJ
Here is some background on the FDA rejecting the drug, which leads me to believe Europe will accept it:
Spoiler [+]
At the time of this post the stock is at a perfect buy in position at 1.27
In the research I was conducting in terms of the FDA I have found some interesting pieces of information that might help in the understanding of the shocking report that the FDA passed in terms of the rejection they placed on Alimeras drug Iluvian which has showed positive clinical results in the studies done.
I started by researching the commissioner of the FDA Dr. Margaret A. Hamburg off the website http://www.fda.gov/AboutFDA/CentersOffic... which I wanted to know more about her which led me to her short bio here http://en.wikipedia.org/wiki/Margaret_Ha... which if you read will talk about her family which is where it gets interesting, as her husband is the renown Peter Fitzhugh Brown and placed as a "artificial intelligence researcher" under Wikipedia. What they fail to mention and upon a simple google search reveals that he is the CO-Chief Executive Officer, CO-President, Director of a company called Renaissance Technologies Corp which upon further research is one of the largest hedge funds in the US with over 15 billion dollars worth of assets and also a large investor in a company called Regeneron Pharmaceuticals Inc which if you can imagine also developed a drug similar to Iluvian called Eylea. Now although Mr. Brown did not directly invest into Regeneron his hedge fund was one of the firms that profited the most from the FDA approval http://www.gurufocus.com/news/122988/reg... Jim Simons is the name that you will be looking for as he is the CEO/ Founder of the firm. The most interesting part about all of this is that the drug they are now selling was accepted only a few days after Alimera was denied approval for side effects, or unclear data for clinical trials when in fact the drug Eylea was causing "bleeding of the conjunctiva, eye pain, cataracts, detachment of the retina from the vitreous humor, and greater pressure within the eye. In a few patients, strokes, nonfatal heart attacks, and vascular death, including deaths of unknown cause, occurred. Those side effects occurred in about 1.8 percent of patients combined.", this article can be found here http://www.journaltimes.com/lifestyles/h...
Seems weird to me that Iluvian provides a safer alternative than Eylea, lasts 3 years which the other requires an injection every other month at a cost of 1800 and 300 a visit to have done. Seems weird that the FDA commissioners husbands firm is an investor in a similar but yet more dangerous drug that is approved just days after Iluvian is shot down for approval. The pharm firms stock price went up 13.5 percent once accepted and the fund stepped away pretty nice.
This just comes to show that the approval from Europe is very likely as the FDA seems to be scamming companies that meet and/or exceed qualifications and approves those who have close ties with the commissioner herself.
http://messages.finance.y...1782&tof=5&frt=2
In the research I was conducting in terms of the FDA I have found some interesting pieces of information that might help in the understanding of the shocking report that the FDA passed in terms of the rejection they placed on Alimeras drug Iluvian which has showed positive clinical results in the studies done.
I started by researching the commissioner of the FDA Dr. Margaret A. Hamburg off the website http://www.fda.gov/AboutFDA/CentersOffic... which I wanted to know more about her which led me to her short bio here http://en.wikipedia.org/wiki/Margaret_Ha... which if you read will talk about her family which is where it gets interesting, as her husband is the renown Peter Fitzhugh Brown and placed as a "artificial intelligence researcher" under Wikipedia. What they fail to mention and upon a simple google search reveals that he is the CO-Chief Executive Officer, CO-President, Director of a company called Renaissance Technologies Corp which upon further research is one of the largest hedge funds in the US with over 15 billion dollars worth of assets and also a large investor in a company called Regeneron Pharmaceuticals Inc which if you can imagine also developed a drug similar to Iluvian called Eylea. Now although Mr. Brown did not directly invest into Regeneron his hedge fund was one of the firms that profited the most from the FDA approval http://www.gurufocus.com/news/122988/reg... Jim Simons is the name that you will be looking for as he is the CEO/ Founder of the firm. The most interesting part about all of this is that the drug they are now selling was accepted only a few days after Alimera was denied approval for side effects, or unclear data for clinical trials when in fact the drug Eylea was causing "bleeding of the conjunctiva, eye pain, cataracts, detachment of the retina from the vitreous humor, and greater pressure within the eye. In a few patients, strokes, nonfatal heart attacks, and vascular death, including deaths of unknown cause, occurred. Those side effects occurred in about 1.8 percent of patients combined.", this article can be found here http://www.journaltimes.com/lifestyles/h...
Seems weird to me that Iluvian provides a safer alternative than Eylea, lasts 3 years which the other requires an injection every other month at a cost of 1800 and 300 a visit to have done. Seems weird that the FDA commissioners husbands firm is an investor in a similar but yet more dangerous drug that is approved just days after Iluvian is shot down for approval. The pharm firms stock price went up 13.5 percent once accepted and the fund stepped away pretty nice.
This just comes to show that the approval from Europe is very likely as the FDA seems to be scamming companies that meet and/or exceed qualifications and approves those who have close ties with the commissioner herself.
http://messages.finance.y...1782&tof=5&frt=2
